Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pembrolizumab infusion · 1 trial · 4 indications
pCR in eligible stage IIA-IIIB (N2) NSCLC participants (AJCC Version 8, no known sensitizing EGFR or ALK alterations) following neoadjuvant pembrolizumab plus chemotherapy
Post-treatment proportion of CXCL13+PD1+ CD8 T cells in all CD8 T cells in single cell RNA-seq data
| Arm | Type | Description |
|---|---|---|
| Pembrolizumab + Chemotherapy | EXPERIMENTAL | Non-squamous NSCLC: pembrolizumab 200mg as at least 30-minute IV infusion on Day 1, followed by pemetrexed at a dose of 500mg/m2 IV over 30 minutes or per institutional standard with Carboplatin at a dose of AUC 5 over 120 minutes or per institutional standard, of a 3-week treatment cycle, for up to 4 cycles. Squamous NSCLC: pembrolizumab 200mg as at least 30-minute IV infusion on Day 1, followed by nab-paclitaxel at a dose of 135mg/m2 IV over 30 minutes or per institutional standard with Carboplatin at a dose of AUC 5 over 120 minutes or per institutional standard, of a 3-week treatment cycle, for up to 4 cycles. Nab-paclitaxel will also be administered at the dose of 135mg/m2 for over 30 minutes IV infusion or per institutional standard on day 8 of each 3-week treatment cycle. |
| Name | Type | Description |
|---|---|---|
| Pembrolizumab 200 mg IV infusion | BIOLOGICAL | Biological: Pembrolizumab 200 mg IV infusion Drug: nab-paclitaxel IV infusion Drug: Carboplatin IV infusion Drug: Pemetrexed IV infusion |
Inclusion Criteria: 1. Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of \[Stage II, IIIA or IIIB(N2) NSCLC (AJCC Version 8)\] will be enrolled in this study. Note: mixed cellularity tumors are allowed. tu...
Pembrolizumab infusion is used for the treatment of Stage IIIB(N2) Non-small Cell Lung Cancer. It is being studied in combination with chemotherapy as neoadjuvant and adjuvant therapy for this condition. The drug is a monoclonal antibody being developed by Merck & Company, Inc. for this oncology indication.
Pembrolizumab infusion is a monoclonal antibody that belongs to the -mab (antibody) target class. As an antibody-based therapy, it is designed to interact with specific molecular targets involved in cancer progression. The drug is being evaluated in a biomarker-selected patient population for Non-small Cell Lung Cancer.
Pembrolizumab infusion is developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this monoclonal antibody for the treatment of Stage IIIB(N2) Non-small Cell Lung Cancer and other related stages of the disease.
Pembrolizumab infusion is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug has received a Priority Review designation from the FDA, indicating it is being evaluated for expedited review, but it remains in active clinical testing.
Pembrolizumab infusion is being studied in clinical trial NCT05894889, titled 'Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC'. This Phase 2 trial is active but not recruiting, with an enrollment of 70 participants. The trial is being conducted in China and includes patients with Stage IIIB(N2), Stage IIA, Stage IIB, and Stage IIIA Non-small Cell Lung Cancer.
Yes, Pembrolizumab infusion is also known as Pembrolizumab 200 mg IV infusion. Both names refer to the same drug product, which is administered as an intravenous infusion at a 200 mg dose. This naming is used in clinical and prescribing contexts for the monoclonal antibody therapy.